SERPINB9 and lymphoma: In a separate study, Kimman et al. explored CD19 and CD20 CAR T killing using a PI9 knockdown lymphoma cell line and demonstrated that at a 1:1 E:T ratio, killing frequencies were similarly not impacted [43].